Top

Published in:

01-08-2013 | Topic Review

MicroRNA biomarkers in glioblastoma

Authors: Simon Kjær Hermansen, Bjarne Winther Kristensen

Published in: Journal of Neuro-Oncology | Issue 1/2013

Abstract

Recent research suggests that deregulation of microRNAs (miRNAs) is involved in initiation and progression of many cancers, including gliomas and that miRNAs hold great potential as future diagnostic and therapeutic tools in cancer. MiRNAs are a class of short non-coding RNA sequences (18–24 nucleotides), which base-pair to target messenger RNA (mRNA) and thereby cause translational repression or mRNA degradation based on the level of complementarity between strands. Profiling miRNAs in clinical glioblastoma samples has shown aberrant expression of numerous miRNAs when compared to normal brain tissues. Understanding these alterations is key to developing new biomarkers and intelligent treatment strategies. This review presents an overview of current knowledge about miRNA alterations in glioblastoma while focusing on the clinical future of miRNAs as biomarkers and discussing the strengths and weaknesses of various methods used in evaluating their expression.

Available only for authorised users

Louis DN, Ohgaki H, Wiestler OD et al (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466PubMedCrossRef

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRef

Zhang W, Zhang J, Hoadley K et al (2012) MiR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol 14(6):712–719PubMedCrossRef

Zhi F, Chen X, Wang S et al (2010) The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 46(9):1640–1649PubMedCrossRef

Hermansen SK, Dahlrot RH, Nielsen BS et al (2012) MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol 111(1):71–81PubMedCrossRef

Doleshal M, Magotra AA, Choudhury B et al (2008) Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 10(3):203–211PubMedCrossRef

Xi Y, Nakajima G, Gavin E et al (2007) Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13(10):1668–1674PubMedCrossRef

Pasquinelli AE (2012) MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 13(4):271–282PubMed

10.

Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861–874PubMedCrossRef

11.

Kim VN, Han J, Siomi MC (2009) Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10(2):126–139PubMedCrossRef

12.

Yi R, Qin Y, Macara IG et al (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17(24):3011–3016PubMedCrossRef

13.

Lee Y, Ahn C, Han J et al (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956):415–419PubMedCrossRef

14.

Kiriakidou M, Nelson P, Lamprinaki S et al (2005) Detection of microRNAs and assays to monitor microRNA activities in vivo and in vitro. Methods Mol Biol 309:295–310PubMed

15.

Elbashir SM, Lendeckel W, Tuschl T (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15(2):188–200PubMedCrossRef

16.

Liao JY, Ma LM, Guo YH et al (2010) Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of miRNAs and tRNA 3′ trailers. PLoS ONE 5(5):e10563PubMedCrossRef

17.

Place RF, Li LC, Pookot D et al (2008) MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 105(5):1608–1613PubMedCrossRef

18.

Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457(7228):426–433PubMedCrossRef

19.

Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854PubMedCrossRef

20.

Reinhart BJ, Slack FJ, Basson M et al (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403(6772):901–906PubMedCrossRef

21.

Pasquinelli AE, Reinhart BJ, Slack F et al (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408(6808):86–89PubMedCrossRef

22.

Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99(24):15524–15529PubMedCrossRef

23.

Friedman RC, Farh KK, Burge CB et al (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92–105PubMedCrossRef

24.

Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10(10):704–714PubMedCrossRef

25.

Ciafre SA, Galardi S, Mangiola A et al (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334(4):1351–1358PubMedCrossRef

26.

Niyazi M, Zehentmayr F, Niemöller OM et al (2011) MiRNA expression patterns predict survival in glioblastoma. Radiat Oncol 6:153PubMedCrossRef

27.

Guan P, Yin Z, Li X et al (2012) Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res 31(1):54PubMedCrossRef

28.

Schetter AJ, Harris CC (2011) Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol 38(6):734–742PubMedCrossRef

29.

Le Quesne J, Caldas C (2010) Micro-RNAs and breast cancer. Mol Oncol 4(3):230–241PubMedCrossRef

30.

Fabbri M, Croce CM (2011) Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol 18(4):266–272PubMedCrossRef

31.

Lee EJ, Gusev Y, Jiang J et al (2007) Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120(5):1046–1054PubMedCrossRef

32.

Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14):6029–6033PubMedCrossRef

33.

Gaur A, Jewell DA, Liang Y et al (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67(6):2456–2468PubMedCrossRef

34.

Godlewski J, Nowicki MO, Bronisz A et al (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68(22):9125–9130PubMedCrossRef

35.

Silber J, Lim DA, Petritsch C et al (2008) MiR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6:14PubMedCrossRef

36.

Lukiw WJ, Cui JG, Li YY et al (2009) Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). J Neurooncol 91(1):27–32PubMedCrossRef

37.

Sasayama T, Nishihara M, Kondoh T et al (2009) MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 125(6):1407–1413PubMedCrossRef

38.

Lavon I, Zrihan D, Granit A et al (2010) Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol 12(5):422–433PubMed

39.

Lages E, Guttin A, El Atifi M et al (2011) MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS ONE 6(5):e20600PubMedCrossRef

40.

Lang MF, Yang S, Zhao C et al (2012) Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS ONE 7(4):e36248PubMedCrossRef

41.

Takamizawa J, Konishi H, Yanagisawa K et al (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64(11):3753–3756PubMedCrossRef

42.

Guan Y, Mizoguchi M, Yoshimoto K et al (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 16(16):4289–4297PubMedCrossRef

43.

Jiang L, Mao P, Song L et al (2010) MiR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol 177(1):29–38PubMedCrossRef

44.

Lakomy R, Sana J, Hankeova S et al (2011) MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 102(12):2186–2190PubMedCrossRef

45.

Wu Z, Sun L, Wang H et al (2012) MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS ONE 7(10):e47270PubMedCrossRef

46.

Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189–4199PubMedCrossRef

47.

Srinivasan S, Patric IR, Somasundaram K (2011) A ten-microRNA expression signature predicts survival in glioblastoma. PLoS ONE 6(3):e17438PubMedCrossRef

48.

Baraniskin A, Kuhnhenn J, Schlegel U et al (2011) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol 14(1):29–33PubMedCrossRef

49.

Teplyuk NM, Mollenhauer B, Gabriely G et al (2012) MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol 14(6):689–700PubMedCrossRef

50.

Malzkorn B, Wolter M, Liesenberg F et al (2009) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20(3):539–550PubMedCrossRef

51.

Rao SA, Santosh V, Somasundaram K (2010) Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 23(10):1404–1417PubMedCrossRef

52.

Li D, Chen P, Li XY et al (2011) Grade-specific expression profiles of miRNAs/mRNAs and docking study in human grade I–III astrocytomas. OMICS 15(10):673–682PubMedCrossRef

53.

Kim H, Huang W, Jiang X et al (2010) Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci USA 107(5):2183–2188PubMedCrossRef

54.

Permuth-Wey J, Thompson RC, Burton Nabors L et al (2011) A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. J Neurooncol 105(3):639–646PubMedCrossRef

55.

Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518PubMedCrossRef

56.

Wang Q, Li P, Li A et al (2012) Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res 31(1):97PubMedCrossRef

57.

Ilhan-Mutlu A, Wagner L, Wohrer A et al (2012) Plasma microRNA-21 concentration may be a useful biomarker in glioblastoma patients. Cancer Invest 30(8):615–621PubMedCrossRef

58.

Ilhan-Mutlu A, Wagner L, Wohrer A et al (2012) Blood alterations preceding clinical manifestation of glioblastoma. Cancer Invest 30(9):625–629PubMedCrossRef

59.

Yang C, Wang C, Chen X et al (2013) Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 132(1):116–127PubMedCrossRef

60.

Li J, Smyth P, Flavin R et al (2007) Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 7:36PubMedCrossRef

61.

Hall JS, Taylor J, Valentine HR et al (2012) Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer 107(4):684–694PubMedCrossRef

62.

Aldridge S, Hadfield J (2012) Introduction to miRNA profiling technologies and cross-platform comparison. Methods Mol Biol 822:19–31PubMedCrossRef

63.

Git A, Dvinge H, Salmon-Divon M et al (2010) Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 16(5):991–1006PubMedCrossRef

64.

Jensen SG, Lamy P, Rasmussen MH et al (2011) Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 12:435PubMedCrossRef

65.

Ach RA, Wang H, Curry B (2008) Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. BMC Biotechnol 8:69PubMedCrossRef

66.

Chen Y, Gelfond JA, McManus LM et al (2009) Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics 10:407PubMedCrossRef

67.

Nelson PT, Wang WX, Wilfred BR et al (2008) Technical variables in high-throughput miRNA expression profiling: much work remains to be done. Biochim Biophys Acta 1779(11):758–765PubMedCrossRef

68.

Nielsen BS, Jørgensen S, Fog JU et al (2011) High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 28(1):27–38PubMedCrossRef

69.

Jørgensen S, Baker A, Møller S et al (2010) Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 52(4):375–381PubMedCrossRef

70.

Sempere LF, Preis M, Yezefski T et al (2010) Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors. Clin Cancer Res 16(16):4246–4255PubMedCrossRef

71.

Rask L, Balslev E, Jørgensen S et al (2011) High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. APMIS 119(10):663–673PubMedCrossRef

72.

Wienholds E, Kloosterman WP, Miska E et al (2005) MicroRNA expression in zebrafish embryonic development. Science 309(5732):310–311PubMedCrossRef

73.

Kloosterman WP, Wienholds E, de Bruijn E et al (2006) In situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide probes. Nat Methods 3(1):27–29PubMedCrossRef

74.

Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10(1):57–63PubMedCrossRef

75.

Weng L, Wu X, Gao H et al (2010) MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol 222(1):41–51PubMed

76.

Schulte JH, Marschall T, Martin M et al (2010) Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res 38(17):5919–5928PubMedCrossRef

77.

Fang X, Yoon JG, Li L et al (2011) The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics 12:11PubMedCrossRef

78.

Weller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6(1):39–51PubMedCrossRef

Title: MicroRNA biomarkers in glioblastoma
Authors: Simon Kjær Hermansen
Bjarne Winther Kristensen
Publication date: 01-08-2013
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2013
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1155-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MicroRNA biomarkers in glioblastoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer

The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme

New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy

Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide

Early and late postoperative seizure outcome in 97 patients with supratentorial meningioma and preoperative seizures: a retrospective study

MR perfusion in and around the contrast-enhancement of primary CNS lymphomas